Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

185.90 +1.25 (+0.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 830,880
Open 183.81
Bid (Size) 185.56 (1)
Ask (Size) 186.50 (3)
Prev. Close 184.65
Today's Range 182.80 - 186.53
52wk Range 181.31 - 268.30
Shares Outstanding 144,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Looking Into Biogen's Recent Short Interest
Via Benzinga
Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024
From Biogen Inc.
Via GlobeNewswire

Performance

YTD
-30.56%
-30.56%
1 Month
-5.06%
-5.06%
3 Month
-17.97%
-17.97%
6 Month
-4.23%
-4.23%
1 Year
-26.63%
-26.63%

More News

Read More
After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce
Via Benzinga
Topics Workforce
Exposures Layoff
Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock
Via Benzinga
Exposures Product Safety
The Latest Analyst Ratings For Biogen
Via Benzinga
Looking Into Biogen's Recent Short Interest
Via Benzinga
Forecasting The Future: 20 Analyst Projections For Biogen
Via Benzinga
Key Takeaways From Biogen Analyst Ratings
Via Benzinga
Eli Lilly's Alzheimer's Drug Raises Hopes but Faces Regulatory Hurdles in Europe
Via Benzinga
Large-Cap Stocks In Trouble - Sunday, Oct. 13
Via Talk Markets
These 3 Stocks Are Screaming Oversold: Seize the Opportunity
Via MarketBeat
Topics ETFs Earnings
Exposures Financial
Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
From Biogen Inc.
Via GlobeNewswire
After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study
Via Benzinga
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
From Biogen Inc.
Via GlobeNewswire
Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year
Via Benzinga
Exposures Product Safety
1 Unstoppable Growth Stock Heading to $2 Trillion by 2030
Via The Motley Fool
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate
Via Benzinga
Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial
Via Benzinga
UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
From Biogen Inc.
Via GlobeNewswire
Biogen Board Appoints Two New Independent Directors
From Biogen Inc.
Via GlobeNewswire
Zepbound And Mounjaro Maker Eli Illy Has A New CFO As It Navigates Regulatory Challenges: What You Should Know
Via Benzinga
Bernie Sanders Says If You're Poor In America You'll Live 10-15 Years Less: 'Anybody Else See A Problem With That?'
Via Benzinga
Biogen/Eisai's Leqembi Brings Hope To Early Alzheimer's Patients Amid Logistical Challenges
Via Benzinga
Biogen's Higher Dose Spinraza Shows To Slow Neurodegeneration Faster In Infants With Rare Neuromuscular Disorder
Via Benzinga
Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA
From Biogen Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.